ArticleHematology, transfusion and cell therapy

What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?

Guilherme Rasia Bosi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.